Table 2.
Antibody responses in IEI patients.
| Patient No. | Vaccine brand | Route | Disease category | S-RBD IgG post-dose 2 | WT sVNT post-dose 2 (%) | BA.1 sVNT post-dose 2 (%) | S-RBD IgG post-dose 3 | WT sVNT post-dose 3 (%) | BA.1 sVNT post-dose 3 (%) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BB | MM | Dysregulation | 2.07 | 97.14 | 38.09 | / | / | / |
| 2 | BB | MM | Humoral | 0.25 | 15.00 | 10.00 | / | / | / |
| 3 | BB | MM | Humoral | 0.25 | 15.00 | 10.00 | / | / | / |
| 4 | BB | MM | Innate | 1.81 | 95.50 | 10.00 | / | / | / |
| 6 | BBB | MMD | Combined | 2.00 | 93.15 | 10.00 | 2.47 | 95.87 | 10.00 |
| 7 | BBB | MMD | Dysregulation | 2.22 | 92.72 | 10.00 | 2.80 | 95.43 | 10.00 |
| 8 | BBB | MMD | Humoral | / | / | / | 2.59 | 96.09 | 31.22 |
| 9 | BBB | MMD | Innate | 1.60 | 87.19 | 10.00 | 1.93 | 87.18 | / |
| 10 | BBB | MMM | Combined | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | 10.00 |
| 11 | BBB | MMM | Combined | 2.22 | 95.06 | 10.00 | / | / | / |
| 12 | BBB | MMM | Dysregulation | 1.59 | 81.51 | 10.00 | 2.96 | 96.79 | / |
| 13 | BBB | MMM | Humoral | 0.25 | 15.00 | 10.00 | 0.25* | 15.00* | / |
| 14 | BBB | MMM | Humoral | 0.25 | 15.00 | 10.00 | 1.82 | 72.21 | / |
| 15 | BBB | MMM | Humoral | 0.25 | 15.00 | 10.00 | 3.37 | 97.32 | 68.88 |
| 16 | BBB | MMM | Innate | 1.49 | 79.97 | 10.00 | 2.21 | 92.45 | / |
| 17 | BBB | MMM | Innate | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | 10.00 |
| 18 | BBB | MMM | Phagocytic | 2.49 | 91.22 | 10.00 | 2.79 | 97.21 | 10.00 |
| 19 | BBB | MMM | Phagocytic | 1.97 | 96.51 | 21.88 | 2.97 | 96.61 | 88.19 |
| 20 | BBB | MMM | Phagocytic | 2.49 | 96.25 | 10.00 | 2.75 | 97.23 | 85.47 |
| 22 | CC | MM | Humoral | 0.25* | 15.00* | / | / | / | / |
| 23 | CC | MM | Humoral | 0.25 | 15.00 | / | / | / | / |
| 25 | CC | MM | Phagocytic | 2.26 | 85.24 | / | / | / | / |
| 26 | CCC | DDD | Combined | 0.25 | 15.00 | 10.00 | 0.25* | 15.00* | / |
| 27 | CCC | DDD | Innate | 1.59 | 82.25 | / | / | / | / |
| 28 | CCC | MMM | Dysregulation | 2.44 | 86.13 | / | 2.12 | 90.25 | / |
| 29 | CCC | MMM | Dysregulation | 1.75 | 93.07 | 10.00 | 2.06 | 92.00 | 28.96 |
| 30 | CCC | MMM | Humoral | 2.30 | 79.20 | / | / | / | / |
| 31 | CCC | MMM | Humoral | 2.52 | 91.19 | / | / | / | / |
| 32 | CCC | MMM | Humoral | / | / | / | 1.15 | 60.42 | / |
| 33 | CCC | MMM | Humoral | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | 10.00 |
| 34 | CCC | MMM | Humoral | 0.25 | 15.00 | 10.00 | 1.20 | 50.96 | 10.00 |
| 35 | CCC | MMM | Humoral | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | 10.00 |
| 36 | CCC | MMM | Humoral | 0.25 | 15.00 | 10.00 | 1.06 | 15.00 | 10.00 |
| 37 | CCC | MMM | Humoral | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | 10.00 |
| 38 | CCC | MMM | Phagocytic | 1.51 | 88.88 | 10.00 | 2.17 | 97.42 | / |
| 39 | CCC | MMM | Phagocytic | 0.25 | 15.00 | 10.00 | 0.25 | 15.00 | / |
* denotes results samples taken after breakthrough infection. S-RBD IgG and sVNT results are given as OD450 values and % inhibition respectively. Negative S-RBD IgG, WT sVNT and BA.1 sVNT results were imputed as 0.25, 15 and 10 respectively. B, BNT162b2; C, CoronaVac; M (route), intramuscular; D, intradermal.